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Dear Editor,
With great interest, we read the article by Tripodi et al. [1]
investigating the changes of global hemostatic parameters in
patients with myeloproliferative neoplasms (MPN). The au-
thors aimed to study whether global tests would be able to
detect a “procoagulant imbalance” that correlates with an
increased risk for thromboembolism in patients with MPN
and to propose a measure for risk assessment and follow-up
in clinical trials. This issue is in line with efforts to establish
global measures of bleeding and thrombotic risks in a variety
of clinical situations [2, 3]. However, the most important
questions to give an answer on this issue are as follows: (1)
Do the changes represent the thrombotic risk or are they a
consequence of confounding variables? (2) Is the degree of
changes relevant? We feel that these issues require critical
appraisal.
The authors compared thromboelastometry measure-
ments in patients with essential thrombocythemia (ET),
primary myelofibrosis (IMF), and polycythemia vera
(PV) with healthy controls. The median platelet count
(PLT) in ET and IMF patients was much higher than that
in PV patients and healthy controls ([1], Table 1). The
influence of PLT on thromboelastometry parameters is
well-established [4], and our group was able to show
that PLT is a major factor of influence, independent from
other factors that may affect coagulation (Fig. 1) [5].
Thus, it seems likely that observed changes are the result
of a varying PLT and not an “intrinsic procoagulant
imbalance”. This is promoted by the fact that no differ-
ences have been found in PV patients ([1], Figure 3).
Another issue is that the investigation is based on the
assumption that patients with MPN have a “procoagulant
imbalance” in general. Most patients were on antiplatelet
therapy, phlebotomy, and cytoreductive therapy, which are
effective measures to reduce the thromboembolic risk in
MPN patients [6]. We are convinced that a study aiming to
propose a measure for risk assessment and follow-up must be
done using clinical outcomes such as thromboembolic events
or at least established risk factors of thromboembolic events in
MPN patients [7].
The authors report on two out of nine parameters of
INTEM test. A median maximum clot firmness (MCF) of
68 mm in ET and IMF (range 56–76 and 57–78, respec-
tively) was reported versus 61 mm in healthy controls
(range 51–68 mm). CFT was 47 s (30–91) in ET, 53 s
(34–104) in IMF, and 71 s in controls (range 47–121).
The differences were stated to be statistically significant
(p<0.05), but it was not reported if the analysis was
corrected for multiple testing (nine parameters of INTEM
test). Furthermore, given the large variability and recog-
nized problems in reproducibility [8–10], it has to be
discussed which degree of changes is considered as rele-
vant to promote its use in clinical practice and scientific
inquiry.
Development of global measures of bleeding and
thrombotic risks is an important issue in thrombosis
and hemostasis research. However, all validity aspects
have to be mentioned to be of value in scientific inquiry
and clinical practice.
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Fig. 1 Changes of
thromboelastometry parameters
with increasing platelet count.
Results of an in vitro investigation
studying the impact of hematocrit
level (Ht) and platelet count on
thromboelastometry parameters
[5] are shown (maximum clot
firmness (MCF) of the INTEM
test with varying platelet counts at
different Ht; unpublished figure).
Box plots display median, inter-
quartile range, and range
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